Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 8/20 | 0.42 |
| ▸ | CCR4 | P51679 | 12/20 | 0.42 |
| ▸ | EHMT1 | Q9H9B1 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4525127 | 0.91 | CCR4 (0.41) | EHMT2CCR4EHMT1 | |
| SCHEMBL4526191 | 0.85 | ADRA1D (0.47) | EHMT2CCR4EHMT1 | |
| SCHEMBL4520397 | 0.83 | KMT5A (0.42) | EHMT2CCR4EHMT1 | |
| SCHEMBL4521403 | 0.80 | WHR1 (0.43) | EHMT2CCR4EHMT1 | |
| SCHEMBL4526326 | 0.77 | CCR4 (0.44) | EHMT2CCR4EHMT1 | |
| SCHEMBL4526182 | 0.76 | EGFR (0.41) | CCR4 | |
| SCHEMBL4524523 | 0.76 | WHR1 (0.46) | EHMT2CCR4 | |
| SCHEMBL4524546 | 0.76 | WHR1 (0.46) | EHMT2CCR4 | |
| SCHEMBL4520353 | 0.75 | WHR1 (0.44) | EHMT2CCR4EHMT1 | |
| SCHEMBL4529415 | 0.74 | WHR1 (0.46) | EHMT2CCR4EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | claimed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | EHMT2 3659/4885CCR4 2557/4885EHMT1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.